CU20140060A7 - 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato - Google Patents
4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidratoInfo
- Publication number
- CU20140060A7 CU20140060A7 CU2014000060A CU20140060A CU20140060A7 CU 20140060 A7 CU20140060 A7 CU 20140060A7 CU 2014000060 A CU2014000060 A CU 2014000060A CU 20140060 A CU20140060 A CU 20140060A CU 20140060 A7 CU20140060 A7 CU 20140060A7
- Authority
- CU
- Cuba
- Prior art keywords
- amino
- carboxamide
- phenyl
- monohidrate
- trifluorometil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Containers And Plastic Fillers For Packaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere al compuesto -{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxiI}-N-metilpiridina-2-carboxamida, sus sales y su monohidrato.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10004022 | 2010-04-15 | ||
PCT/EP2011/055508 WO2011128261A1 (en) | 2010-04-15 | 2011-04-08 | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20140060A7 true CU20140060A7 (es) | 2014-10-02 |
Family
ID=44070712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20120147A CU24123B1 (es) | 2010-04-15 | 2011-04-08 | Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato |
CU2014000060A CU20140060A7 (es) | 2010-04-15 | 2014-05-26 | 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20120147A CU24123B1 (es) | 2010-04-15 | 2011-04-08 | Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato |
Country Status (39)
Country | Link |
---|---|
US (5) | US8748622B2 (es) |
EP (1) | EP2558448B1 (es) |
JP (1) | JP5934182B2 (es) |
KR (2) | KR20170129276A (es) |
CN (2) | CN103980191A (es) |
AR (2) | AR081060A1 (es) |
AU (1) | AU2011240113B2 (es) |
BR (1) | BR112012026117B1 (es) |
CA (1) | CA2796238C (es) |
CL (1) | CL2012002840A1 (es) |
CO (1) | CO6630136A2 (es) |
CR (1) | CR20120526A (es) |
CU (2) | CU24123B1 (es) |
DK (1) | DK2558448T3 (es) |
DO (2) | DOP2012000268A (es) |
EC (1) | ECSP12012234A (es) |
ES (1) | ES2542610T3 (es) |
GT (1) | GT201200280A (es) |
HK (1) | HK1200831A1 (es) |
HR (1) | HRP20150885T1 (es) |
HU (1) | HUE026821T2 (es) |
IL (2) | IL222348B (es) |
JO (1) | JO3158B1 (es) |
MA (1) | MA34156B1 (es) |
MX (1) | MX2012011734A (es) |
MY (2) | MY177066A (es) |
NZ (1) | NZ602997A (es) |
PE (2) | PE20130181A1 (es) |
PL (1) | PL2558448T3 (es) |
PT (1) | PT2558448E (es) |
RS (1) | RS54219B1 (es) |
RU (1) | RU2581585C2 (es) |
SG (2) | SG10201501221UA (es) |
SI (1) | SI2558448T1 (es) |
TN (1) | TN2012000492A1 (es) |
TW (2) | TWI539951B (es) |
UA (1) | UA110613C2 (es) |
UY (2) | UY33290A (es) |
WO (1) | WO2011128261A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA91520C2 (en) * | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
UY35006A (es) | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
CA2885688C (en) | 2012-09-25 | 2021-03-02 | Bayer Pharma Aktiengesellschaft | Combination of regorafenib and acetylsalicylic acid for treating cancer |
CN104250227A (zh) * | 2013-06-29 | 2014-12-31 | 广东东阳光药业有限公司 | 瑞戈非尼新晶型及其制备方法 |
WO2015049698A2 (en) * | 2013-10-04 | 2015-04-09 | Hetero Research Foundation | Process for regorafenib |
CN105218439B (zh) * | 2014-06-06 | 2018-11-20 | 连云港润众制药有限公司 | 一种瑞格非尼的晶体及其制备方法 |
US9790185B2 (en) | 2014-07-09 | 2017-10-17 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
CN104557689B (zh) * | 2015-01-26 | 2016-06-29 | 重庆两江药物研发中心有限公司 | 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法 |
CN104592105B (zh) * | 2015-02-10 | 2017-01-18 | 杭州朱养心药业有限公司 | 瑞戈非尼及其制法 |
CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
US20190300484A1 (en) * | 2016-01-18 | 2019-10-03 | Natco Pharma Ltd | An improved process for the preparation of regorafenib |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
PL3630112T3 (pl) | 2017-06-02 | 2024-07-01 | Bayer Healthcare Llc | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu |
CN109438337B (zh) * | 2018-11-27 | 2019-08-09 | 广东安诺药业股份有限公司 | 一种瑞戈非尼中间体的制备工艺 |
CN109438336B (zh) * | 2018-11-27 | 2019-11-22 | 广东安诺药业股份有限公司 | 一种瑞戈非尼水合物的制备方法 |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
WO2021160708A1 (en) | 2020-02-14 | 2021-08-19 | Bayer Aktiengesellschaft | Combination of regorafenib and msln-ttc for treating cancer |
CN114315710B (zh) * | 2022-01-07 | 2024-04-26 | 江苏豪森药业集团有限公司 | 一种制备或纯化瑞戈非尼的方法 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
PT2305255E (pt) | 2001-12-03 | 2012-09-04 | Bayer Healthcare Llc | Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos |
WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
ME00294B (me) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
CA2564325A1 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
CN101048140B (zh) | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | 用于治疗癌症的药物组合物 |
UA91520C2 (en) | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
SI1797037T1 (sl) | 2004-09-29 | 2015-06-30 | Bayer Healthcare Llc | Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2009513706A (ja) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ソラフェニブを用いた癌の治療 |
JP2009515978A (ja) | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
JP2010509253A (ja) * | 2006-11-09 | 2010-03-25 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 4−[4−({[4−クロロ−3−(トリフルオロメチル)フェニル]カルバモイル}アミノ)−3−フルオロフェノキシ]−n−メチルピリジン−2−カルボキサミドの多形iii |
JP2010509382A (ja) * | 2006-11-14 | 2010-03-25 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 4−[4−({[4−クロロ−3−(トリフルオロメチル)フェニル]カルバモイル}アミノ)−3−フルオロフェノキシ]−n−メチルピリジン−2−カルボキサミドの多形ii |
EP2111401B1 (en) | 2006-12-20 | 2011-02-16 | Bayer HealthCare, LLC | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
WO2008089388A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
EP2129376B1 (en) | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
CA2741087A1 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
RU2011150619A (ru) | 2009-05-15 | 2013-06-20 | Новартис Аг | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
WO2013000917A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing regorafenib |
CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
US8841500B2 (en) | 2011-11-08 | 2014-09-23 | Chevron U.S.A. Inc. | Preparation of alkyl aromatic compounds |
JP2014032346A (ja) | 2012-08-06 | 2014-02-20 | Japan Display Inc | 液晶表示パネル |
UY35006A (es) | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
-
2011
- 2011-03-23 AR ARP110100982A patent/AR081060A1/es not_active Application Discontinuation
- 2011-03-24 UY UY0001033290A patent/UY33290A/es active IP Right Grant
- 2011-04-08 KR KR1020177032906A patent/KR20170129276A/ko not_active Application Discontinuation
- 2011-04-08 ES ES11712881.9T patent/ES2542610T3/es active Active
- 2011-04-08 PL PL11712881T patent/PL2558448T3/pl unknown
- 2011-04-08 MX MX2012011734A patent/MX2012011734A/es active IP Right Grant
- 2011-04-08 NZ NZ602997A patent/NZ602997A/en unknown
- 2011-04-08 CU CU20120147A patent/CU24123B1/es active IP Right Grant
- 2011-04-08 DK DK11712881.9T patent/DK2558448T3/en active
- 2011-04-08 SI SI201130559T patent/SI2558448T1/sl unknown
- 2011-04-08 KR KR1020127026728A patent/KR101800041B1/ko active IP Right Grant
- 2011-04-08 MA MA35304A patent/MA34156B1/fr unknown
- 2011-04-08 WO PCT/EP2011/055508 patent/WO2011128261A1/en active Application Filing
- 2011-04-08 CN CN201410248545.4A patent/CN103980191A/zh active Pending
- 2011-04-08 AU AU2011240113A patent/AU2011240113B2/en active Active
- 2011-04-08 BR BR112012026117-7A patent/BR112012026117B1/pt active IP Right Grant
- 2011-04-08 MY MYPI2016001879A patent/MY177066A/en unknown
- 2011-04-08 SG SG10201501221UA patent/SG10201501221UA/en unknown
- 2011-04-08 CA CA2796238A patent/CA2796238C/en active Active
- 2011-04-08 EP EP20110712881 patent/EP2558448B1/en active Active
- 2011-04-08 PT PT117128819T patent/PT2558448E/pt unknown
- 2011-04-08 PE PE2012002008A patent/PE20130181A1/es active IP Right Grant
- 2011-04-08 JP JP2013504206A patent/JP5934182B2/ja active Active
- 2011-04-08 PE PE2016000780A patent/PE20160838A1/es unknown
- 2011-04-08 MY MYPI2012004548A patent/MY162359A/en unknown
- 2011-04-08 RS RS20150528A patent/RS54219B1/en unknown
- 2011-04-08 HU HUE11712881A patent/HUE026821T2/en unknown
- 2011-04-08 CN CN201180019150.1A patent/CN102947271B/zh active Active
- 2011-04-08 SG SG2012069852A patent/SG184172A1/en unknown
- 2011-04-08 RU RU2012148386/04A patent/RU2581585C2/ru active
- 2011-04-08 US US13/640,959 patent/US8748622B2/en active Active
- 2011-04-13 JO JOP/2011/0125A patent/JO3158B1/ar active
- 2011-04-14 TW TW103141317A patent/TWI539951B/zh active
- 2011-04-14 TW TW100112905A patent/TWI475992B/zh active
- 2011-08-04 UA UAA201212983A patent/UA110613C2/uk unknown
-
2012
- 2012-10-08 EC ECSP12012234 patent/ECSP12012234A/es unknown
- 2012-10-10 CL CL2012002840A patent/CL2012002840A1/es unknown
- 2012-10-11 GT GT201200280A patent/GT201200280A/es unknown
- 2012-10-11 IL IL222348A patent/IL222348B/en active IP Right Grant
- 2012-10-12 TN TNP2012000492A patent/TN2012000492A1/en unknown
- 2012-10-12 CO CO12180992A patent/CO6630136A2/es not_active Application Discontinuation
- 2012-10-12 DO DO2012000268A patent/DOP2012000268A/es unknown
- 2012-10-16 CR CR20120526A patent/CR20120526A/es unknown
-
2014
- 2014-04-15 US US14/252,850 patent/US9458107B2/en active Active
- 2014-05-26 CU CU2014000060A patent/CU20140060A7/es unknown
-
2015
- 2015-02-10 HK HK15101433.6A patent/HK1200831A1/xx unknown
- 2015-08-19 HR HRP20150885TT patent/HRP20150885T1/hr unknown
-
2016
- 2016-09-08 US US15/259,576 patent/US20170057918A1/en not_active Abandoned
- 2016-10-20 DO DO2016000285A patent/DOP2016000285A/es unknown
-
2017
- 2017-06-22 IL IL253119A patent/IL253119B/en active IP Right Grant
- 2017-08-03 US US15/668,178 patent/US20170334857A1/en not_active Abandoned
-
2019
- 2019-01-09 US US16/243,284 patent/US10822305B2/en active Active
- 2019-09-13 AR ARP190102596A patent/AR116395A2/es unknown
-
2021
- 2021-12-23 UY UY0001039590A patent/UY39590A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20140060A7 (es) | 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato | |
UA109924C2 (uk) | Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція | |
BR112013033511A8 (pt) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)ethóxi)fenil)butil)carbamimidoil) pirazina-2-carboxamida | |
UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
DK3130347T3 (da) | PH20-polypeptidvarianter, formuleringer og anvendelser deraf | |
DK2760444T3 (da) | Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf | |
RS54642B1 (en) | MEGLUMIN SO 6-FLUOR-3-HYDROXY-2-PYRAZINE CARBOXAMIDE | |
UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
BR112013010834A2 (pt) | polipeptídeos fator ix modificados e usos dos mesmos | |
UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
UA110880C2 (uk) | Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів | |
UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
UA22925S (uk) | Переносний інформаційний термінал | |
EA201390074A1 (ru) | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения | |
EA201490450A1 (ru) | Новые ингибиторы ферментов | |
UY34211A (es) | ?métodos y composiciones para producir arroz resistente a inhibidores de accasa?. | |
UY34442A (es) | 2-tiopirimidinonas. | |
UY4153Q (es) | Batería | |
HN2008001859A (es) | Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. | |
UY34791A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida | |
FR2982157B1 (fr) | Composition cosmetique ou dermatologique comprenant un alpha-alcoxysilane a base uree ou amide | |
UA118008C2 (uk) | Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою | |
EA201301235A1 (ru) | Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
IT1399461B1 (it) | Ramosa. | |
UA111156C2 (uk) | Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою |